Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand.
Department of Radiation Oncology, National Cancer Institute of Thailand, Bangkok, Thailand.
Radiother Oncol. 2022 Sep;174:77-86. doi: 10.1016/j.radonc.2022.07.009. Epub 2022 Jul 15.
To investigate the vaginal 11-point and volumetric dose-toxicity relationships in definitive cervical cancer radiotherapy.
A retrospective cohort study of patients with cervical cancer with a complete response of at least 12 months was performed. Additional per vaginal examinations and patient-scoring questionnaires on the date of patient enrolment were assessed for vaginal strictures. Retrospective dosimetric analysis of vaginal 11-point and volumetric doses was performed with descriptive and probit analyses to investigate dose-toxicity relationships.
Ninety-seven patients were included in the study, with a 20-month median follow-up. The incidence rate of grade 3 vaginal strictures was 22.7%. A comparison between patients with grade 1-3 vaginal strictures revealed significant differences in age, stage, initial tumour size, and vaginal involvement. PIBS + 2, PIBS, PIBS-2, D + 5, and D2cc were all significantly different among grade 1-3 vaginal strictures and showed significant probit coefficients. The lateral dose points were significantly higher in grade 2 strictures, but negative probit coefficients failed to establish causal inferences. Post-estimation analyses yielded effective doses (ED) for 15% and 20% probability of grade 3 vaginal strictures (ED15 and ED20) for PIBS + 2 at 57.4 and 111 Gy, respectively. PIBS-2 yielded an ED20 of 7 Gy. D + 5 yielded positive ED10, ED15, and ED20 values of 52.2, 66.6, and 78 Gy, respectively.
This study showed a significant relationship between age, tumour size, and lower-third vaginal involvement with the incidence of vaginal toxicity. The goal of a cumulative radiotherapy dose of ≤ 55 Gy to PIBS + 2, ≤5 Gy to PIBS-2, and ≤ 65 Gy to D + 5 points may reduce the risk of grade 3 vaginal stenosis to less than 15-20%.
研究宫颈癌根治性放疗中阴道 11 点和体积剂量-毒性关系。
对至少 12 个月完全缓解的宫颈癌患者进行回顾性队列研究。在患者入组当天,对阴道狭窄进行了额外的阴道检查和患者评分问卷调查。通过描述性和概率分析对阴道 11 点和体积剂量进行回顾性剂量分析,以研究剂量-毒性关系。
本研究共纳入 97 例患者,中位随访时间为 20 个月。Grade 3 阴道狭窄的发生率为 22.7%。对比 grade 1-3 阴道狭窄患者,年龄、分期、初始肿瘤大小和阴道受累均有显著差异。PIBS+2、PIBS、PIBS-2、D+5 和 D2cc 在 grade 1-3 阴道狭窄中均有显著差异,且概率系数显著。grade 2 狭窄的侧位剂量点明显较高,但负概率系数未能建立因果关系。后估计分析得出,PIBS+2 导致 grade 3 阴道狭窄的概率为 15%和 20%时的有效剂量(ED)分别为 57.4 和 111 Gy;PIBS-2 导致 ED20 为 7 Gy;D+5 导致 ED10、ED15 和 ED20 分别为 52.2、66.6 和 78 Gy,均为正值。
本研究表明,年龄、肿瘤大小和阴道下段受累与阴道毒性的发生有显著关系。PIBS+2 累积放疗剂量≤55 Gy、PIBS-2≤5 Gy、D+5 点≤65 Gy 的目标可能将 grade 3 阴道狭窄的风险降低到 15-20%以下。